<DOC>
	<DOCNO>NCT00986661</DOCNO>
	<brief_summary>This open-label study evaluate safety , tolerability , pharmacokinetics effect tumor growth follow single intralesional injection PV-10 subject either ( ) hepatocellular carcinoma ( HCC ) amenable resection , transplant potentially curative therapy ( b ) cancer metastatic liver .</brief_summary>
	<brief_title>A Study Assess PV-10 Chemoablation Cancer Liver</brief_title>
	<detailed_description>Subject enrol one three plan cohort ( Main Study Group , Expansion Cohort 1 Expansion Cohort 2 ) . Main Study Group . Three initial subject either HCC cancer metastatic liver receive 0.25 mL PV-10 per cc lesion volume ( Lv ) single lesion ( maximum dose 7.5 mL PV-10 ) . If none initial three subject experience new persistent CTCAE Grade 3 great non-hematological Grade 4 hematological toxicity 28-day follow-up interval , additional three subject enrol similarly treat PV-10 administer 0.50 mL per cc Lv ( maximum dose 15 mL PV-10 ) provide new persistent Grade 3 great non-hematological Grade 4 hematological toxicity occur . Expansion Cohort 1 ( EC1 ) . Following demonstration safety tolerability Main Study Group , 48 additional subject cancer metastatic liver recurrent HCC enrol expansion cohort . Subjects treat PV-10 administer 0.50 mL per cc Lv ( maximum dose 15 mL PV-10 ) . Enrollment continue provide new persistent Grade 3 great non-hematological ( exclude fatigue ) Grade 4 hematological toxicity occur . Expansion Cohort 2 ( PV-10 plus Sorafenib ) . Following demonstration safety tolerability Main Study Group , 6 additional subject HCC receive sorafenib dose stable tolerable least 4 week enrol two successive dose group Expansion Cohort 2 . The first 3 subject assign Expansion Cohort 2.1 ( EC2.1 ) receive PV-10 administer 0.25 mL PV-10 per cc Lv ( maximum dose 7.5 mL PV-10 ) . If none initial 3 subject experience dose-limiting toxicity ( DLT ) , define onset Grade 3 great non-hematological ( exclude fatigue ) Grade 4 hematological toxicity within 28 day PV-10 administration persistent 14 day longer , enrollment Expansion Cohort 2.2 commence . If 2 initial 3 subject experience DLT , combination PV-10 sorafenib PV-10 dose level judge intolerable . If one initial 3 subject experience DLT , additional 3 subject enrolled Expansion Cohort 2.1 . If none additional subject experience DLT , enrollment Expansion Cohort 2.2 commence . If 1 3 additional subject ( i.e. , ≥ 2 6 subject ) experience DLT , combination PV-10 sorafenib PV-10 dose level judge intolerable . If Expansion Cohort 2.1 complete tolerable toxicity , enrollment Expansion Cohort 2.2 ( EC2.2 ) commence dose 0.5 mL PV-10 per cc Lv ( maximum dose 15 mL PV-10 ) . If none 1 first 3 subject enrol experience DLT , cohort expand 6 subject . If 1 subject among 6 experience DLT , dose 0.5 mL PV-10 per cc Lv judge maximum tolerable dose ( MTD ) study . If 2 6 subject experience DLT , combination PV-10 sorafenib PV-10 dose level judge intolerable . If Expansion Cohort 2.2 dose tolerate , Expansion Cohort 2.1 expand 6 subject , unless already occur . If 1 subject 6 experience DLT , Expansion Cohort 2.1 dose PV-10 plus sorafenib judge intolerable . Otherwise , Expansion Cohort 2.1 dose MTD study . Subjects Expansion Cohort 1 Expansion Cohort 2 one injectable tumor ≥ 1 cm diameter eligible treatment additional injectable tumor 28 day 120 day prior PV-10 administration provide prior treatment PV-10 well tolerate . This may repeat injectable tumor ≥ 1 cm diameter receive PV-10 .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<mesh_term>Neoplasms</mesh_term>
	<criteria>Age 18 year old , male female . Histologically cytologically confirm , clinically diagnose base currently accept standard , cancer metastatic liver HCC amenable time enrollment resection , transplant potentially curative therapy . The Target Lesion must determine amenable percutaneous injection treat physician . The Target Lesion must measurable disease , define unidimensionally measurable lesion ≥ 1.0 cm long diameter helical CT ; maximum diameter Target Lesion shall ≤ 4.9 cm . Performance status Karnofsky scale 60 % 100 % ECOG performance scale 02 . Life expectancy ≥ 12 week . Hematopoietic Function : WBC ≥ 2,500/mm3 ; ANC ≥ 1000/mm3 ; Hemoglobin ≥ 8 g/dL ; Platelet count ≥ 50,000/mm3 ; Coagulation : INR ≤ 1.3 . AST ALT &lt; 5 time ULN ; ALP &lt; 5 time ULN ; Bilirubin ≤ 1.5 time ULN ; Creatinine ≤ 1.5 time ULN eGFR ≥ 50 . Thyroid Function : Total T3 free T3 , total T4 free T4 THS ≤ CTCAE Grade 2 abnormality . Renal Function : Adequate renal function opinion Investigator clinically significant renal impairment uncontrolled renal disease . Cardiovascular Function : Adequate cardiovascular function opinion Investigator clinically significant uncontrolled cardiovascular disease . Respiratory Function : Adequate respiratory function opinion Investigator clinically significant uncontrolled respiratory disease . Immunological Function : Adequate immune system function opinion Investigator know immunodeficiency disease . Informed Consent : Signed subject prior screen . Target Lesion ( ) must contiguous , encompass infiltrate major blood vessel . Primary HCC amenable resection , transplant potentially curative therapy . Surgery : Subjects receive hepatic surgery , ablation chemoembolization within 4 week PV10 administration . Radiation Therapy : Hepatic radiation within 4 week PV10 administration . Chemotherapy : Chemotherapy within 4 week PV10 administration ( 6 week nitrosoureas mitomycin C ) . Subjects HCC stable dose sorafenib least 4 week candidate enrollment Expansion Cohort 2 . Investigational Agents : Investigational agent within 4 week ( 5 halflives ) PV10 administration . Phototoxic Photosensitizing Agents : Concomitant agent pose clinically significant risk photosensitivity reaction within 5 halflives PV10 administration . Concurrent Intercurrent Illness : Impaired wound heal due diabetes ; Significant concurrent intercurrent illness , psychiatric disorder alcohol chemical dependence would compromise Subject safety compliance interfere interpretation study ; Uncontrolled thyroid disease cystic fibrosis ; Presence clinically significant acute unstable cardiovascular , cerebrovascular ( stroke ) , renal , gastrointestinal , pulmonary , immunological ( exception presence hepatitis B virus ( HBV ) , viral hepatitis , cirrhosis ) , endocrine , central nervous system disorder ; Current encephalopathy current treatment encephalopathy ; Variceal bleed require hospitalization transfusion within 4 month screen ; History human immunodeficiency virus acquire immune deficiency syndrome ; The clinical presence ascites . Pregnancy : Female subject pregnant , lactate positive serum β HCG pregnancy test take within 7 day PV10 administration ; Fertile subject use effective contraception ( e.g. , oral contraceptive , intrauterine device , double barrier method condom diaphragms , abstinence equivalent measure ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>